Reduced frequency is very encouraging for patient compliance and could help those who dislike weekly injections and ...

According to a factsheet published by the Trump administration, pharmaceuticals are exempted from the tariffs – for now.

The FDA has granted accelerated approval to Novartis’ Vanrafia for adults with primary immunoglobulin A nephropathy (IgAN).

Astellas Pharma has entered a strategic partnership with the JFCR to expedite research in translational and clinical oncology ...

T2D has been associated with an increased risk of CV mortality and GLP-1RAs are being increasingly used as a T2D and obesity ...

At the BioTrinity Conference, experts champion government funding programmes to bridge gap the in UK venture capital ...

But while platform trials have the potential to be more effective and less expensive than traditional trials, challenges ...

Organon has announced the acquisition from Biogen of US regulatory and commercial rights for intravenous infusion of ...

The push for reducing funding and the workforce at the FDA comes partly from US Secretary of Health and Human Services Robert ...

Panellists at the OBN BioTrinity 2025 conference in London discussed how US uncertainty is impacting the biopharma environment.

Amneal Pharmaceuticals and Shilpa Medicare have launched the new presentation of bortezomib, Boruzu, for subcutaneous or ...

GlobalData predicts that tirzepatide is likely to be increasingly prescribed for broader cardiometabolic disease.